The Q-Collar, a neck collar inspired by the woodpecker, has gained popularity among NFL players and young athletes as a potential way to reduce concussion risk. Initially marketed as a device that lightly squeezes the jugular veins to stabilize the brain, it later shifted its focus to claiming brain protection. With millions of dollars raised and FDA authorization, the Q-Collar seemed like a promising solution for head injuries in sports.
However, a recent investigation by The BMJ uncovered serious reservations from FDA reviewers regarding the device. Internal memos revealed discussions about weak data, discrepancies between MRI findings and real-world injury outcomes, and doubts about the statistical findings presented by the company. Despite these concerns, the official press release announcing FDA authorization in 2021 portrayed a sense of triumph.
The Q-Collar was authorized through the de novo pathway as a Class II device, indicating moderate risk. While FDA authorization may seem synonymous with approval to consumers, it actually allows marketing based on a “reasonable assurance of safety and effectiveness” when the data are suggestive but not definitive. This can lead to a misleading sense of certainty about the product’s efficacy.
The marketing of products like the Q-Collar often implies reduced risk of concussions, tapping into public fears about head injuries in sports. While these devices may not claim to prevent concussions, the promise of protection from the long-term effects of repeated head impacts is alluring to consumers. However, the effectiveness of such products is difficult to verify on an individual level, creating a self-reinforcing cycle where any lack of injury is seen as validation.
Recent incidents, such as the concussion suffered by the Jets’ Sauce Gardner while wearing the Q-Collar, highlight the limitations of these devices. Despite such setbacks, the FDA’s authorization lends a sense of legitimacy that reinforces belief in the product. This dynamic not only impacts sports but also sets a precedent for regulatory decisions in other industries.
The push for innovation and the allure of profits without proof create a moral hazard that can divert attention and resources from truly effective interventions. Transparency is crucial in building trust with consumers, and reforms such as publishing reviewer memos and providing plain-language labeling can help bridge the gap between authorization and proven efficacy. Genuine transparency is essential for fostering trust and ensuring that products like the Q-Collar are held to rigorous standards of evidence.
In conclusion, while the Q-Collar and similar devices have the potential to address head injuries in sports, greater transparency and accountability are needed to ensure that they deliver on their promises. By shedding light on the reasoning behind FDA authorizations and the limitations of the evidence, we can build a more informed and trustworthy healthcare landscape.
